Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Epic Sciences Talks Differentiation And Benefits Of Its DefineMBC Cancer Test

Executive Summary

Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.

You may also be interested in...



Sysmex picks neighbouring Asian CTC firm for liquid biopsy collaboration

Japanese hematology diagnostics heavyweight Sysmex is partnering with Clearbridge BioMedics, an emerging Singapore company in the field of circulating tumor cell capture technology, to co-develop a new liquid biopsy system for diagnosing and monitoring cancer patients.

INTERVIEW: Roche backing to help speed Liquid Biopsy's CTC test development

Liquid Biopsy, a Swedish firm developing a test for circulating tumour cells (CTCs) for the diagnosis, prognosis and monitoring of cancer, has highlighted the importance of new partner Roche in developing the test for clinical use.

INTERVIEW: New Angle for CTC capture device Parsortix; approval within a year?

Parsortix, a blood-based diagnostic that captures and counts circulating tumour cells (CTCs) for the diagnosis, prognosis and monitoring of cancer, could be approved in around a year, according to Angle, the company developing the device.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT145538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel